The Latest Breaking News from Obesity

Obesity is a growing public health concern, and its impact extends to pregnancy. Women who are obese are at an increased risk of both maternal and fetal complications during pregnancy. It can pose significant risks and considerations for both the mother and the baby.

In recent years, there has been a concerning trend of reduced physical activity among school children. Sedentary lifestyles, driven by increased screen time and academic pressures, contribute to this decline. This lack of physical activity poses significant health risks, including obesity, cardiovascular issues, and mental health challenges. Urgent action is…

Of late, the cases of sudden cardiac arrest even among women are on the rise due to unhealthy lifestyles and extreme stress. Most of the working women hardly manage time for a daily workout. Less physical activity, Long working hours, sleep deprivation due to the use of smartphones at home…

Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's stock market, too. Here's why NVO is a must-own stock.

Childhood obesity and demoralised NHS staff are among the biggest problems for Keir Starmer, says Prof Devi Sridhar, chair of global public health at the University of Edinburgh

A doctor argues that the current focus on fighting obesity with drugs like Ozempic ignores the bigger picture: We need a medical system and society that support healthy life habits.

"A systematic review of all studies that looked at the impact of fermented foods on satiety . . . showed no effect"

Loss of muscle mass also flagged, as UK drugmaker works with China’s Eccogene on obesity and type 2 diabetes pill

Healthcare stocks LLY and NVO have crushed broader market returns in the past two decades. But with competition heating up over obesity drugs, which mega-cap stock is a better buy today?

Bariatric surgery is more effective at controlling hypertension rates, or high blood pressure, in people with obesity and uncontrolled high blood pressure, than blood pressure medication alone. Read further on Dynamite News:

Drug manufacturer Amgen Inc. (AMGN) is actively pursuing strategic collaborations and making noteworthy strides in the realm of obesity treatments. With the company all set to lift the curtains on its fiscal fourth-quarter earnings tomorrow, would it be prudent to take a bullish stance on the stock now? Keep reading…